NATHAN FOWLER to Cytarabine
This is a "connection" page, showing publications NATHAN FOWLER has written about Cytarabine.
Connection Strength
0.176
-
Intensive chemoimmunotherapy and bilateral globe irradiation as initial therapy for primary intraocular lymphoma. Neuro Oncol. 2016 Apr; 18(4):575-81.
Score: 0.082
-
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (=65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncol. 2022 03; 23(3):406-415.
Score: 0.032
-
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. Cancer. 2018 06 15; 124(12):2561-2569.
Score: 0.024
-
Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol. 2015 Nov; 171(4):509-16.
Score: 0.020
-
Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol. 2013 Dec; 163(5):611-20.
Score: 0.018